B. Riley receives Nasdaq notice over annual report delay
(Reuters) - B. Riley Financial said on Friday it had received a delinquency notification letter from the Nasdaq following a delay in the filing of its annual report.
While the notice has no immediate effect on B. Riley's listing, the Nasdaq has informed the company that it must submit a plan by June 2 to address how it intends to regain compliance with listing rules.
The company's annual report was due on March 17.
Reuters reported in March that B. Riley co-CEO Bryant Riley has dropped plans to take the investment bank private.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Lululemon Stock Falls as Forecasts Reflect Consumer Caution
The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite tariff-related concerns. After retreating from record highs over the past few sessions, shares of data analytics firm Palantir bounced back, boosted by a signal of robust AI demand. Shares of Lululemon plummeted after the apparel maker cut its outlook for the current quarter and the full year, citing soft consumer U.S. equities indexes pushed higher to close out the trading week. The Bureau of Labor Statistics reported that the U.S. economy added 139,000 jobs in May, topping economists' forecasts and helping alleviate concerns about a tariff-driven slowdown in the labor market. The S&P 500 gained 1% on Friday, closing above the 6,000-point level for the first time since February. The Dow was up 1.1%, while the Nasdaq jumped 1.2%. Shares of big data analytics software provider Palantir Technologies (PLTR) popped 6.5% higher, securing the top daily performance in the S&P 500. Positivity around its expanding government business helped lift Palantir to an all-time high on Tuesday, but before Friday's gains, the stock had been pulling back for a couple of sessions. Palantir and other artificial intelligence companies benefited from upbeat sentiment after earnings results from chipmaker Broadcom (AVGO) revealed strong AI demand. Moderna (MRNA) shares wrapped up a volatile week of trading with a gain of 5.1% on Friday. The biotech company announced at the end of last week that it had received Food and Drug Administration (FDA) approval for the use of its new COVID-19 vaccine by older and higher-risk patients. On Tuesday, Health and Human Services Secretary Robert F. Kennedy Jr. said Moderna had agreed to a placebo-controlled trial of the vaccine. United Airlines (UAL) announced a partnership with Spotify Technology (SPOT) that will allow airborne passengers to access playlists, audiobooks, and video podcasts from the streaming service on their seatback screens. United shares increased 4.8% on Friday, while rival carrier Delta Air Lines (DAL) shares were up 4.3%. Tesla (TSLA) shares advanced 3.7% on Friday as the feud between Tesla CEO Elon Musk and U.S. President Donald Trump showed signs of de-escalation heading into the weekend. The spat between the two contributed to a major drop in the electric vehicle (EV) maker's stock in the prior session. Several analysts reaffirmed their bullishness on Tesla despite the high-profile conflict, but they noted that the tensions with Trump could complicate the regulatory path for the firm's self-driving technology or risk alienating people with certain political perspectives. Lululemon Athletica (LULU) issued lower-than-expected sales and profit guidance for the current quarter and trimmed its full-year profit forecast. The maker of yoga attire and other athletic apparel noted that U.S. consumers are taking a cautious approach to spending and discussed plans to increase prices on some products as it aims to mitigate tariff impacts. Lululemon shares plunged 19.8% on Friday, dropping the most of any constituent in the S&P 500. JPMorgan and UBS analysts cut their price targets on Lululemon stock following the underwhelming outlook. Broadcom posted fiscal second-quarter sales and adjusted profit results that were roughly in line with consensus forecasts. A major year-over-year uptick in artificial intelligence semiconductor revenue helped the chipmaker achieve record quarterly revenue of $15 billion. However, Broadcom shares slipped 5% on Friday, receding from a string of record highs notched before the earnings release. Mosaic (MOS), a provider of fertilizers and other agricultural products, reduced its 2025 phosphate production guidance, citing operational issues at its U.S. facilities. Shares of Mosaic were down 4.4%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
Yahoo
41 minutes ago
- Yahoo
Tesla's Optimus humanoid robot program head exiting firm, Bloomberg News reports
(Reuters) -The head of Tesla's Optimus program, Milan Kovac, is leaving the company, casting uncertainty over chief executive Elon Musk's humanoid robot project, Bloomberg News reported on Friday, citing a person familiar with the matter. Kovac, vice president and head of engineering for Optimus, told colleagues on Friday that he was departing, effective immediately. Ashok Elluswamy, who leads Tesla's autopilot teams, will take on Kovac's role, the report said. Tesla, Kovac and Elluswamy did not immediately respond to Reuters requests for comment. Musk has earlier said he expected Tesla to make thousands of Optimus robots this year. He said in April that China's export restrictions on rare-earth magnets had affected production of the humanoid robots. Tesla has shifted focus to launching the robots and its robotaxi service, with much of the company's valuation hanging on that bet. "The only things that matter in the long term are autonomy and Optimus," Musk told CNBC in an interview in May.
